Related Experiment Video
Updated: Jul 10, 2026
06:02
Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
Cationic liposomes as vaccine adjuvants
Dennis Christensen1, Karen S Korsholm, Ida Rosenkrands
1Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, 81/306, DK-2300 Copenhagen S, Copenhagen, Denmark. den@ssi.dk
Expert Review of Vaccines
|October 13, 2007
Summary
Cationic liposomes, positively charged vesicles, are emerging as advanced vaccine adjuvants. They protect antigens, enhance immune cell delivery, and modulate immune responses for targeted diseases.
Area of Science:
- Biotechnology
- Immunology
- Materials Science
Background:
- Cationic liposomes are lipid-bilayer vesicles with a positive surface charge.
- They are being re-evaluated as a promising new adjuvant technology for vaccines.
Purpose of the Study:
- To review recent advancements in cationic liposomes as vaccine adjuvants.
- To highlight their role in enhancing immunomodulator effects and antigen presentation.
Main Methods:
- Literature review of recent progress in cationic liposome technology.
- Analysis of the functions of cationic liposomes in vaccine adjuvant systems.
Main Results:
- Cationic liposomes protect vaccine antigens from rapid clearance.
- They facilitate the delivery of antigens to professional antigen-presenting cells.
- They can incorporate immunomodulators to tailor immune responses.
Conclusions:
- Cationic liposomes are versatile vehicles for vaccine development.
- They offer efficient strategies for designing tailor-made adjuvants.
- Their application enhances antigen presentation and immunomodulation for specific disease targets.
